REMS stands for Risk Evaluation and Mitigation Strategy, a drug safety program that the FDA can require for medications with serious safety concerns. Think of it as an extra layer of safeguards beyond the standard prescription process. When a drug’s benefits are significant but its risks are potentially severe, a REMS creates specific rules that patients, doctors, and pharmacies must follow before the medication can be prescribed, dispensed, or continued.
Congress gave the FDA this authority through the Food and Drug Administration Amendments Act of 2007, and hundreds of medications have been subject to REMS requirements since then. Some programs are straightforward, requiring only that patients receive written safety information. Others are far more involved, requiring blood tests, pregnancy screenings, doctor certifications, and patient registries before a single pill can be dispensed.
How a REMS Program Works
Not every REMS looks the same. The FDA tailors each program to the specific risks of the drug, and the requirements can range from simple to highly restrictive. Every REMS uses one or more of four main components.
- Medication Guide or Patient Package Insert: FDA-approved documents written in patient-friendly language that explain the drug’s serious risks. These are required when knowing the risks could affect your decision to start or continue treatment, or when following the directions precisely is crucial for the drug to work safely.
- Communication Plan: Materials directed at healthcare providers (not patients) to make sure doctors and pharmacists understand the risks. This can include letters sent to prescribers or information distributed through professional medical societies.
- Elements to Assure Safe Use (ETASU): The most restrictive tier. These are mandatory actions that must happen before a drug is prescribed or dispensed. They can include requiring doctors to complete specialized training, certifying pharmacies, limiting where a drug can be given (such as hospitals only), enrolling patients in registries, or requiring ongoing lab monitoring.
- Implementation System: The behind-the-scenes infrastructure that monitors whether pharmacies, hospitals, and prescribers are actually following the ETASU rules and working to improve compliance over time.
What REMS Means for Patients
If you’re prescribed a medication that has a REMS, you’ll likely encounter extra steps before you can fill your prescription. The most common is a patient-prescriber agreement, a form you and your doctor both sign that confirms you’ve been counseled about the drug’s risks and understand what’s involved. This agreement sometimes doubles as an enrollment form, registering you in the REMS program so the drug manufacturer can verify that safety conditions have been met before your pharmacy releases the medication.
Depending on the drug, you may also need lab work before starting treatment and at regular intervals afterward. For medications that cause birth defects, your prescriber may need to determine whether you could become pregnant, and if so, pregnancy testing becomes part of the process. Some programs categorize patients by risk level. For example, the REMS programs for certain cancer drugs classify patients into one of six risk categories based on their potential to be sexually active or become pregnant, with different forms and requirements for each category.
Ongoing monitoring is common too. Even after you’ve started treatment, REMS programs may require periodic check-ins to watch for dangerous side effects and confirm you’re still an appropriate candidate for the medication.
What Doctors and Pharmacies Must Do
REMS programs don’t just add steps for patients. Prescribers and pharmacies often face their own certification requirements. A doctor may need to complete specialized training and formally enroll in a REMS program before they’re allowed to write a prescription for the drug. Pharmacies face a parallel process: they must enroll, designate an authorized representative, and agree to verification systems that check the prescriber’s enrollment status every time the medication is dispensed.
This creates a chain of accountability. The pharmacy checks that the doctor is certified. The doctor checks that the patient meets the safety criteria. And the REMS program tracks all of it. If any link in that chain is missing, the prescription doesn’t get filled.
iPLEDGE: A Real-World Example
One of the most well-known REMS programs is iPLEDGE, which governs isotretinoin, a powerful acne medication that causes severe birth defects. Originally launched in 2005 and formally approved as a REMS in 2010, iPLEDGE requires patients who can become pregnant to undergo pregnancy testing before starting treatment. That initial test must be done in a medical setting.
During and after treatment, follow-up pregnancy tests may be completed at home if the prescriber allows it, but the pre-treatment test always requires a clinical visit. Once a prescription is written, patients have a 7-day window to pick it up. If they miss that window, a repeat pregnancy test is needed, though the FDA has removed the previous “19-day lockout” waiting period that once forced patients to wait weeks before trying again. These requirements reflect how tightly the program controls access to prevent fetal exposure.
How the FDA Monitors REMS Programs
Drug manufacturers don’t just set up a REMS and walk away. The FDA requires regular assessment reports on a defined schedule: at 18 months after initial approval, again at 3 years, and again in the 7th year. Some programs require even more frequent reporting, such as every 6 or 12 months in the early period after approval.
Each assessment evaluates whether the program is actually meeting its safety goals. If the data show that a REMS is too burdensome without meaningfully reducing harm, or that risks are being managed well enough to loosen restrictions, the FDA can modify or even remove the program. This happened recently with the Clozapine REMS, which previously required blood test results to be reported to the REMS program before pharmacies could dispense the drug. The FDA announced it no longer expects prescribers, pharmacies, and patients to participate in the formal REMS program for clozapine, though it still recommends that doctors continue monitoring patients’ blood counts as described in the prescribing information.
How to Look Up REMS Requirements
The FDA maintains a public database called REMS@FDA where anyone can search for active REMS programs. The tool includes a dashboard showing the total number of active programs, which drugs have ETASU requirements, shared-system programs that cover multiple brands of the same drug, and modification histories. If you’ve been prescribed a new medication and want to know whether it carries a REMS, or what that REMS requires, this is the most reliable place to check.